Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL279148 | 0.97 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| Hydrochloric Acid SCHEMBL27879095 | 0.86 | SLC1A1 (0.41) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| Hydrochloric Acid SCHEMBL2840092 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| Hydrochloric Acid SCHEMBL5987780 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| SCHEMBL10458392 | 0.84 | SMN1; SMN2 (0.39) | SMN1; SMN2CA14ALDH1A1CA12KMT2A | |
| SCHEMBL2561278 | 0.82 | — | — | |
| SCHEMBL27554292 | 0.82 | — | — | |
| SCHEMBL27833677 | 0.82 | — | — | |
| SCHEMBL2930776 | 0.82 | — | — | |
| SCHEMBL24016832 | 0.82 | GAA (0.44) | SMN1; SMN2ALDH1A1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634178-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| CN-119156393-A | Cyclic compound, preparation method and medical application thereof | 翰森生物有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| US-20240246990-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | CELGENE INTERNATIONAL II SARL (CH) | 2024-07-25 | — | — | US | disclosed |
| WO-2024126404-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023208005-A1 | CYCLIC COMPOUNDS, PREPARATION METHODS AND MEDICINAL USES THEREOF | HANSOH BIO LLC (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-115103914-A | Preparation method of (1R, 4R, 5S) -4- (2-chloroethyl) -1- ((S) - ((S) -cyclohex-2-en-1-yl) (hydroxy) methyl) -5-methyl-6-oxa-2-azabicyclo [3.2.0] heptane-3, 7-dione (salinosporamide A; marizole) | 细胞基因国际第二责任有限公司 | 2022-09-23 | — | — | CN | disclosed |
| EP-4045671-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | Celgene International II Sàrl (CH) | 2022-08-24 | — | — | EP | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| EP-3935051-A1 | SMALL MOLECULE MODULATORS OF IL-17 | Leo Pharma A/S (DK) | 2022-01-12 | — | — | EP | disclosed |
| US-4705864-A | Aryl oxime derivatives of hydantoins | THE STANDARD OIL COMPANY (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0225874-A1 | FLUXING AGENT AND SOLDERING PROCESS | YTKEMISKA INSTITUTET (SE) | 1987-06-24 | — | — | EP | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| WO-1986000844-A1 | FLUXING AGENT AND SOLDERING PROCESS | YTKEMISKA INSTITUTET (SE) | 1986-02-13 | — | — | WO | disclosed |
| EP-0162217-A1 | 1,2,4-Triazacycloalcadiene derivatives | CIBA-GEIGY AG (CH) | 1985-11-27 | — | — | EP | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
| US-4510141-A | (1,2,4) TRIAZOLO(1,5-A) QUINOXALINE OR PYRIDO(2,3-E)(U,2,4)TRIAZOLO(1,5-A)PYRAZINE COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0074929-A1 | Polycyclic polyazaheterocycles, process for their preparation and pharmaceutical preparations containing them | CIBA-GEIGY AG (CH) | 1983-03-23 | — | — | EP | disclosed |
| US-4130717-A | Process and intermediates for isoindole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-12-19 | — | — | US | disclosed |
| US-4089875-A | Process and intermediates for isoindole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246990-A1 | PROCESS OF PREPARING (1R, 4R, 5S)-4-(2-CHLOROETHYL)-1-((S)-((S)-CYCLOHEX-2-EN-1-YL)(HYDROXY)METHYL)-5-METHYL-6-OXA-2-AZABICYCLO[3.2.0]HEPTANE-3,7-DIONE(SALINOSPORAMIDE A; MARIZOMIB) | PSMA5, EPOR, CYP8B1 | CA2 4480/4885SMN1; SMN2 344/4885CA14 4239/4885 |
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | CA2 1930/4885SMN1; SMN2 4839/4885CA14 3324/4885 |
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | CA2 1751/4885SMN1; SMN2 4850/4885CA14 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.